摘要
目的 研究苯那普利和缬沙坦联合治疗慢性心力衰竭后神经激素的变化及其临床效果。方法 本研究选择 39例慢性心衰患者 (心功能NYHAⅡ～Ⅲ级 ) ,于口服利尿剂的基础上加服苯那普利和缬沙坦 ,治疗 6个月比较心功能及血浆肾素活性 (PRA)、血管紧张素Ⅱ (AngⅡ )、醛固酮(ALD)浓度的变化 ;以 2 1例口服苯那普利的慢性心衰患者为对照组。结果 两组ALD均下降 ,苯那普利 +缬沙坦组>苯那普利组 ,且有统计学意义 (P <0 0 1)。两组在用药后心功能均得到改善 ,但无统计学差异 (P >0 0 5 )。结论 缬沙坦与苯那普利合用可更完全抑制慢性心衰患者过度激活的RAS ,且心功能与治疗前相比得到进一步改善 ,以及有良好的耐受性。
Objectives To investigate the efficacy and safety of valsartan and benazepril combined administered in chronic heart failure(CHF)patients. Methods Sixty CHF(NYHA class Ⅱ～Ⅲ)patients were divided into two groups randomly. One group were administered benazepril (21 cases),the other were administered valsartan and benazepril (39 cases). The triai time were six months. Clinic blood pressure and adverse effects were recorded. Plasma renin activity (PRA),angiotensin (AngⅡ) and aldosterone(ALD) concentration were examined before and after the treatment. Results At the end of 6 months,the combination therapy group elicited a significantly guater reduction on plasma ALD than benazepril monotherapy group (P<0.01). The cariac function were proved in the two groups,but no significantly (P>0.05). Conclusions In this study,combined valsartan and benazepril therapy effectively inhibited renin-angiotensin system (RAS),has generally well tolerance.
出处
《岭南心血管病杂志》
2003年第6期395-397,共3页
South China Journal of Cardiovascular Diseases
